A RUNDOWN REVIEW ON DRUGS CAUSING SEDATIVE AND HYPNOTIC EFFECT

Shruti Saxena[1], Kavyansh Kumar Saxena[2], Lavish Gangwar[3]

1.Student in SRMS College of Engineering and technology, Bareilly- 243202 U.P

2. Student in SRMS College of Engineering and technology, Bareilly- 243202 U.P

3. Student in SRMS College of Engineering and technology, Bareilly- 243202 U.P

ABSTRACT:

Narcotics oversee uneasiness and anxious pressure as they cause sedation, and at times a level of absence of pain, desensitized cognizance with sedation, tend to get rest even at standard restorative portions, which recognize narcotics from sedatives. Spices are generally utilized as an elective medication in rest issues. Presently, sleep deprivation is generally overseen by manufactured sedatives hypnotics; however security in delayed utilization of engineered narcotics and hypnotics has been raised. Throughout recent years, there has been a developing affinity for home grown drugs all over the planet to forestall sleep deprivation. This paper features the need of a characteristic medication to treat a sleeping disorder and rest issue.

KEYWORDS:

Sedative, Hypnotic,Sleep Deprivation, Barbiturates, Benzodiazepene

INTRODUCTION:

Sedative and Hypnotic medications, compound substance used to decrease strain and nervousness and incite quiet (narcotic impact) or to actuate rest (mesmerizing impact). Most such medications apply a calming or quieting impact at low dosages and a rest initiating impact in bigger portions. Narcotic entrancing medications will generally push down the focal sensory system. Since these activities can be gotten with different medications, for example, narcotics, the particular quality of narcotic hypnotics is their specific capacity to accomplish their belongings without influencing state of mind or lessening aversion to torment.

Herbal remedies can treat the problem of Insomnia. Due to the low risk of side effects, many insomniacs are inclined to take medicinal plants[1]. Sleep deprivation (Insomnia) is a typical wellbeing worry that may instigate huge mental and actual problems. In the field of psychological wellness issues, wretchedness, nervousness and sleep deprivation are normal ailments. Impairment of the immune and cardiovascular systems is the association between major depression, insomnia and anxiety disorders[2].

PHARMACOLOGICAL EFFECTS:

The individuals from the sedative-hypnotic class push down the action of all excitable tissue, especially nerve cells. This depressant impact is reversible and its activity is transient on intense organization. The focal sensory system is

wonderfully sensitive to sedative- hypnotics in portions that produce little outcome on skeletal, cardiovascular, or smooth muscle. In bigger portions, as in intense inebriation, the medications can stifle work in cardiovascular action and in other fringe organs.

The abstract impacts are unsurprising and stereotypic in the non tolerant individual for a given member from the sedative-hypnotic class. Early medication impacts are lessened consideration and focus, weakened later or transient memory, happiness, diminished deliberation, decreased mental capacities, and an impression of inebriation. As the blood level builds, the sharpness is fundamentally compromised, state of mind is discouraged, and scholarly capacity is seriously restricted. Loss of cognizance happens in non tolerant people at blood levels significantly lower than those saw in lenient people.

The true impacts are apparent and quantifiable. In coordination of engine developments happens in stride, hand-eye undertakings, saccadic eye pursuit, and trance harmony with generally low portions of medication, so such talented moves as driving an auto or engine execution under hazardous conditions is dangerous. On assessment, the doctor might notice nystagmus, finger-to-nose and heel-to-shin ataxia, and in coordinated fast substituting developments of the hands and pair strolling. Breaths are diminished in number and inside and out, and circulatory strain and heartbeat might be brought down, particularly in higher portions. The tonus of the gastrointestinal musculature and the amplitude of rhythmic contractions are decreased[3.]

The effects from even a single do[se], such as 200 mg of secobarbital, have been shown to interfere with performance of driving or flying for as long as 10 to 22 hours. These aftereffects may be prolonged considerably (i.e., for days) following several successive doses. Many of the drugs will accumulate after repeated administrations, with increasing effects even after the development of tolerance in chronic use[4,5]. In some individuals, particularly those who are very young or who are elderly, a paradoxical excitement occurs in response to single low doses, especially in pain states[6,7].

The impacts from constant utilization of the sedative- hypnotics are comparable for all individuals from the class, and various investigations have reported steady side effects and conditions that go with and follow persistent narcotic mesmerizing use. The essential organ impacted by the medications is the focal sensory system. The significant cerebrum capacities modified by the medications are state of mind, perception, consideration and fixation, knowledge and judgment, memory, and influence and passionate affinity in relational connections. Changes in personality that resemble significant personality disorders may develop in regular users of sedative-hypnotics. Characteristics of antisocial, histrionic, paranoid, and other personality traits can occur in chronic use of these drugs[8].

S.NO.	SEDATIVE AND HYPNOTIC DRUGS
1.	Xanax (Alprazolam)
2.	Librium (Chlordiazepoxide)
3.	Valium (Diazepam)
4.	Ativan (Lorazepam)





MECHANISM OF ACTION OF DRUGS CAUSING SEDATIVE AND HYPNOTIC EFFECT





TOLERANCE AND DEPENDENCE

Two significant types of resistance, pharmacokinetic and pharmacodynamic, create in light of the intense and constant organization of barbiturates. Pharmacokinetic resistance alludes to the assimilation, digestion, and end for attitude of the medication. The calming entrancing drugs are profoundly lipid-dissolvable, having a high lipid to water proportion. The non ionized structure favors lipid dissolvability. In normal portions, the soothing hypnotics are promptly consumed through the gastrointestinal plot into the foundational flow. A rearrangement stage happens, especially with the more lipid-solvent, short-acting narcotic hypnotics, which favors the quick take-up by fat and muscle. In this reallocation the medication vanishes from the circulatory system yet isn't changed or on the other hand wiped out from the body. At the point when the balance is toward the blood compartment, the medication is gradually delivered back to the blood from tissue stockpiling. This peculiarity of reallocation accounts partially for both the brief length of activity and the determination of the medication in the body, which can cause the durable (weeks, months) emotional and social effect.

The barbiturates contend with different substrates that are processed by the cytochrome P-450. The barbiturates furthermore other narcotic hypnotics consolidate with the cytochrome P-450 framework to restrain the biotransformation of those drugs that likewise consolidate with that framework. All the more regularly, no withstanding, the barbiturates cause a checked expansion in the microsomal catalyst framework to speed up the digestion of different medications including the soothing hypnotics themselves. This drug-incited biotransformation of itself and other drugs is one more wellspring of resistance and cross-resilience. Different sedatives, ethanol, and the soothing mesmerizing drugs are utilized by and prompt the microsomal catalysts to deliver multidirectional cross-resilience. Of concern is that extreme enactment of these compounds can cause hazardous intensifications of porphyries in people with discontinuous porphyria.

Pharmacodynamic resistance is a variation that happens at the receptor level. Normally for barbiturates this is a cell change that happens at the layer level. The cell film turns out to be more arranged as resistance creates. Pharmacodynamic resistance creates both intensely also constantly in light of the single or dreary organization of the soothing mesmerizing medications. Intense resilience seems to happen fundamentally sooner than does the enlistment of microsomal proteins because of a solitary portion of barbiturate.

The intense resistance creates without a change in blood level of medication. Constant organization of the medication over significant stretches will bring about a progressive increment in pharmacodynamic resistance provided that the portion is expanded. In any case, the level of pharmacodynamic resistance stays unaltered subsequent to arriving at a top in just a not many long periods of medication organization. Resilience with the impacts on mind-set, sedation, and entrancing happens all the more promptly and is more noteworthy than that to the anticonvulsant and deadly impacts, so the remedial record diminishes with an expansion in resilience. The portion of barbiturate or other narcotic mesmerizing might be expanded six fold as resilience creates. Pharmacokinetic resilience through feeling of microsomal compounds represents simply twofold to triple expansion in the portion, though pharmacodynamic resilience accounts for the remainder.

Reliance on a medication is set apart by the beginning of unsurprising signs and side effects of withdrawal achieved by suspension of its utilization. Organization of the medication during withdrawal will cut short signs and side effects of withdrawal.

Drug use might be kept on balancing the inconvenience of withdrawal, especially assuming that the withdrawal is serious. Withdrawal from narcotic hypnotics is set apart by nervousness and wretchedness that can be particularly serious. The pattern of expanding resistance followed by a more serious reliance that permits further expansions in drug use is frequently finished, be that as it may, by the heightening of the nervousness and discouragement. The withdrawal condition contains a wide cluster of signs furthermore indications. Nervousness and sadness are somewhat consistent.

Others that happen less every now and again can be clinically critical, and some are possibly risky. Quakes, incomplete and summed up seizures, daze, frequently with visual mind flights, and hallucinations, frequently jumpy, show up less normally in the range. The withdrawal disorder from the soothing hypnotics is comparative for all individuals from the class and contrasts just in seriousness and fleeting beginning in the signs and indications. The more limited acting medications ordinarily have a more extreme, prior, and sudden beginning of withdrawal. On the other hand, the more extended acting medications have a milder, afterward, and more progressive beginning of withdrawal. As a helpful dependable guideline, the withdrawal condition for narcotic hypnotics is like that of liquor, which can be utilized as the model for the soothing mesmerizing class of drugs.[9-10]

The presence of resilience and reliance doesn't really imply that fixation has happened. Habit can happen without apparent resistance and reliance. Drug seeking conduct is the sign of compulsion. Compulsion is set apart by distraction with securing, enthusiastic use, furthermore backslide to use after endeavors to go without or cut down. Resistance and reliance every now and again create in enslavement since use is frequently normal and in expanding portions. Resistance also reliance are normal variations of the body to the persevering presence of the medication yet don't flag habit-forming use, as resistance and reliance follow normal utilization of many medications that are not utilized seductively.[11]Tolerance and dependence are guides to the frequent use of a drug, but addiction may or may not be present.

PREVENTION OF SEDATIVE HYPNOTICS LONG RUN USE

Endorsing narcotic mesmerizing medications in clinic considerably affects long haul use.. A case–control study of new benzodiazepine prescriptions found that cases were 3 times more likely than controls to have been admitted to hospital within 30 days after the index date. [12] In another study, at 1 month after discharge, patients were more likely to stop previous benzodiazepine use if they did not receive them during the hospital stay (OR 3.58, 95% CI 1.56 to 8.21) and were more likely to start taking benzodiazepines if they were prescribed them during the hospital stay (OR 3.57, 95% CI 1.66 to 8.08). [13]No writing was distinguished around the job of directing or then again different systems to forestall long haul use.

EFFECTIVE STRATEGIES REQUIRED TO PROHIBIT THE USE OF SEDATIVE-HYPNOTIC

Viable systems, utilized alone or in mix, incorporate basic proposals to stop, tightening conventions, mental social treatment also melatonin. Specifically, there is proof for consolidating tightening conventions with mental social treatment. Mental social treatment is managed by enlisted clinicians and therapists who have gotten unique preparation. Meetings are normally an hour and a half long and frequently happen week after week over a defined period.

Treatments consist of behavioral, cognitive and educational interventions that target different aspects of insomnia. 28 Interventions include sleep restriction (limiting time in bed to actual sleep time), stimulus control (re-associating the bedroom with sleep) and cognitive therapy designed to change faulty beliefs about sleep.[14]
In a cohort study involving 31 patients taking benzodiazepines or a Z drug who received a recommendation to alter their sedative drug use, 68% were adherent at follow-up.[15]

In a trial involving 591 patients, those in the intervention group were given instructions to withdraw, reduce or change psychotropic medications, in addition to a 1-hour lecture about the drugs and their adverse effects. The number of patients who were regular users of benzodiazepines decreased by 35% in the intervention group and increased by 4% in the controls.[16]

Among patients with insomnia who had been using hypnotic-sedative drugs for at least 1 month, cognitive behavioral therapy resulted in significant reductions in Pittsburgh Sleep Quality Index scores from 13 at baseline to 3 at 3-month follow-up to 2 at 6-month follow-up (lower scores indicate reduced severity of sleep disturbance); reductions in sleep latency from 60 minutes at baseline to 28 minutes at 3-month follow-up to 30 minutes at 6-month follow-up; and improvement in sleep efficiency score (representing the percentage of time in bed spent asleep) improved from 2.2 at baseline to 0.7 at both the 3- and 6-month follow-up assessments (Table 1).[17]

Patients who received cognitive behavioral therapy reported reductions in hypnotic drug use (54% reported low-frequency use v. 18% of controls; 33% in the intervention group v. 8% of controls reported zero hypnotic drug use).[17]

Cognitive behavioral therapy in combination with a drug tapering program may result in greater success. In a randomized trial, the frequency of medicated nights was lower and the proportion of benzodiazepine-free patients higher in the combined treatment group than in the groups that received cognitive behavioral therapy only or tapering alone (Table 1) [18.]
There was a 90% overall reduction in the quantity of benzodiazepines used and an 80% overall reduction in the frequency of medicated nights across all 3 treatment groups, which was maintained at 3 and 12 months' follow-up[18].
In a similar trial, a greater proportion of participants in the combined treatment group than in the tapering only group reported completed discontinuation of hypnotic drugs (Table 1). [19]
At the 12-month follow-up, 70% in the combined treatment group, as compared with 24% in the tapering only group, were benzodiazepine free[19].Patients took an average of 7 weeks to stop benzodiazepine use.
In a trial involving 180 long-term benzodiazepine users randomly assigned to tapering plus cognitive behavioral therapy, tapering alone or usual care, discontinuation of benzodiazepine use was significantly more successful in both intervention groups than in the usual care group, with no significant difference between the intervention groups (Table 1) [20].Patients who were using a benzodiazepine other than diazepam were switched to an equivalent dose of diazepam for 2 weeks. If more than one benzodiazepine was being used, the dosages were added together. The daily equivalent dose of diazepam was reduced by 25% per week over 4 weekly visits. Overall, 88% of the physicians found the protocol to be feasible in practice, 83% said they would encourage others to use it, and 52% had already started using it for other patients.[20]

In a randomized trial of a benzodiazepine withdrawal program involving 180 patients, the independent predictors of successful benzodiazepine discontinuation were offering a tapering program (hazard ratio [HR] 2.9, 95% CI 1.8 to 4.8), combining a tapering program with cognitive behavioral group therapy (HR 2.4, 95% CI 1.5 to 3.9), a lower daily benzodiazepine dose at the start (HR 1.5, 95% CI 1.2 to 1.9), a substantial dosage reduction by patients themselves before the tapering protocol (HR 2.1, 95% CI 1.4 to 3.3), less severe benzodiazepine dependence (HR 2.4, 95% CI 1.1 to 5.2), and no concomitant alcohol use (HR 1.7, 95% CI 1.2 to 2.5). [21]

In a placebo-controlled trial involving 38 long-term benzodiazepine users asked by their general practitioner to participate in a discontinuation program in combination with melatonin or placebo, there was no significant difference in outcomes between the groups.[22]
However, among older patients who were encouraged to decrease their benzodiazepine doses while taking melatonin or placebo, sleep quality scores, as measured by the North side Hospital Sleep Medicine Institute Test, were improved in the melatonin group, and 9 of 14 habitual benzodiazepine users were able to discontinue benzodiazepine use.[23]

TABLE 1: Results of randomized controlled trials of the effect of cognitive behavioral therapy on sleep quality:

Table 2: Results of randomized controlled trials of the effect of cognitive behavioural therapy on sleep quality

Study	Duration of treatment	Participants	Mean age, yr	Study group		Outcomes
				Intervention	Comparator	
Morgan et al.[31]	6 wk of active treatment; follow-up at 3 and 6 mo	209 people using benzodiazepines for > 1 mo; mean duration of use 13.4 yr	68	Six 50-min sessions of cognitive behavioural therapy	Usual care with crossover to cognitive behavioural therapy	At 3 mo, intervention group had significant improvement in Pittsburgh scores (mean difference −3.8, 95% CI −4.8 to −2.8), decrease in sleep latency (mean difference −24.1, 95% CI −37.2 to −11.1), improvement in sleep efficiency (mean difference −0.9, 95% CI 1.2 to −0.6) and increase in total sleep time (mean difference 0.5 min, 95% CI 0.1 to 0.8); 47.4% v. 17.3% reported low-frequency use ($p < 0.001$); 30% v. 11% reported zero hypnotic drug use over 7-d follow-up assessment period ($p = 0.005$) At 6 mo, intervention group had significant decrease in sleep latency (mean difference −27.9 min (95% CI −43.4 to −12.6) and improvement in sleep efficiency score (mean difference −1 (95% CI −1.3 to −0.6); 54% v. 18% reported low-frequency use ($p < 0.001$); 33% v. 8% reported zero hypnotic drug use ($p < 0.001$)
Morin et al.[32]	10 wk	76 chronic benzodiazepine users (> 50% of nights for > 3 mo); mean 6.7 nights per wk; mean duration of use 19.3 yr	62.5	Combined benzodiazepine tapering and cognitive behavioural therapy	Benzodiazepine tapering alone or cognitive behavioural therapy alone	Overall, 90% reduction in quantity of benzodiazepine consumption and 80% reduction in frequency of medicated nights across the 3 groups; 63% of patients were benzodiazepine free within 7 wk on average; 85% in combined treatment arm were benzodiazepine free after initial intervention v. 48% in tapering arm and 54% in cognitive behavioural therapy arm
Baillargeon et al.[33]	8 wk	65 daily benzodiazepine users for > 3 mo; mean duration of use 152 mo (12.7 yr)	67.4	Combined benzodiazepine tapering and cognitive behavioural therapy (90-min group session weekly for 8 wk)	Benzodiazepine tapering alone	77% in combined treatment arm v. 38% in tapering arm were benzodiazepine free immediately after treatment (OR 5.3, 95% CI 1.8 to 16.2); this outcome persisted at 12 mo, with 70% benzodiazepine free in combined treatment arm v. 24% in tapering only arm (OR 7.2, 95% CI 2.4 to 23.7)
Voshaar et al.[34]	3 mo	180 regular benzodiazepine users for > 3 mo; mean duration of use 165 mo (13.8 yr)	63.4	Benzodiazepine tapering alone or combined with cognitive behavioural therapy (2-h session weekly for 5 wk)	Usual care	62% in tapering arm and 58% in combined treatment arm were successful with discontinuation v. 21% in usual care arm

Note: CI = confidence interval, OR = odds ratio.

USES OF SEDATIVE-HYPNOTIC DRUGS:

- Treat Sleep Disorders
- Treat Anxiety Disorders
- Prevent/ Cure Seizures
- Relieves Tension
- Treat Panic Disorders
- Alcohol Withdrawal Disorders
- Calm down the person
- Feeling of Relaxation

ADVERSE EFFECTS:

In the older populace, benzodiazepines are most regularly utilized tranquilizers utilized for nervousness and sleep deprivation and furthermore for the treatment of liquor withdrawal, seizure problems, and controlling tumult.

These hypnotics were found to be most effective in reducing sleep latency and improving sleep efficiency with minimal effect on total sleep time[24]. The prevalence of dispensing benzodiazepines and other similar medication increases with increasing age[25.] In the elderly population, long-acting benzodiazepines are avoided as the accumulation of the drug over long periods of use can lead to various adverse effects[26]. Anterograde amnesia can be seen with all benzodiazepines[27]. Adverse effects that may be associated with benzodiazepine use in the elderly include falls, cognitive impairment, sedation, and impairment of driving skills, all of which are particularly related to the long half-life of benzodiazepines[28].

A retrospective study designed to identify the falls leading to hospitalization and death found that in the geriatric population, use of benzodiazepines daily increased the risk of falls (RR = 1.83)[29]. These side effects increase the propensity of falls and cognitive impairment in the elderly, resulting in significant morbidity in this vulnerable age group[30]. In a recent meta-analysis comparing the adverse effects of benzodiazepines in elderly found that use of benzodiazepines in elderly is associated with 2.45 times more risk of side effects when compared with placebo[31]. A Taiwanese study that look at increased risk of hospitalization related to motor vehicle accidents among people taking Zolpidem found that OR for involvement in an motor vehicular accident after taking one defined daily dose of Zolpidem was 1.74 (95% CI 1.25-2.43)[32].

A case series with Zolpidem intoxication delirium has also been reported in elderly patients[33]. A case of Zolpidem induced psychosis has also been reported as well[34]. A case-control study done of hip fracture cases and controls showed that Zolpidem was associated with a significant increased risk of hip fracture (adjusted OR = 1.95, 95% CI = 1.09-3.51)[35]. While suggesting these drugs in this vulnerable population, it should be kept in mind that they should be given for short periods and must be started at lower doses to minimize the risk of adverse effects. An increase in the dose of the drug should be done with proper care and caution.

CONCLUSION:

Sedative hypnotic drugs are usually utilized in the administration of sleep deprivation, which can likewise impede the carefulness of the psycho engine, yet raise wellbeing concerns. These are the Chemical substances which are used to treat, cure and reduce the tension, anxiety and induce calm (sedative effect) or to induce sleep (hypnotic effect). Sedative- Hypnotic drugs are sometimes also called as “DEPRESSANTS” as they depress the CNS function by binding to the GABA receptors and thus show their depressant function. Constant utilization of sedative hypnotics can bring about mental disability, mortality hazard, habit risk, and dementia. Adverse effects include drowsiness, headache, muscle aches, constipation, dry mouth, concentration difficulty, dizziness, instability, and insomnia rebound.

REFERENCES:

1. Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 23(2), 2000, 243-308.
2. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 22, 1999, S347-53.
3. Idestrom CM: Flicker fusion in chronic barbiturate usage: A quantitative study in the pathophysiology of drug addiction. ActaPsychiatricaetNeurologiciaScand 1954; (suppl 91):5-92.
4. Fishman RH, Yanai J: Long lasting effects of early barbiturates on central nervous system and behavior. NeurosciBiobehav Rev 1983; 17(1): 19—28.
5. Okamoto M, Rao S, Walewski JL: Effect of dosing frequency on the development of physical dependence and tolerance to pentobarbital. J PharmacolExpTher 1986; 238:1004-1008.
6. Svensmark O, Buchthal F: Accumulation of phenobarbital in man. Epilepsia 1963; 4:199-206

7. Hay D, Milne RM, Gilleard CT: Hypnotic drugs, old people and theirhabits: A general practice study. Health Bull (Edinb) 1986' 44(4):218-222.
8. Griffiths RR, Bigelow GE, Liehson I: Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry 1983; 40:865-873.
9. Fraser HF, Wilker A, Essia CF, Isbell H: Degree of physical dependence induced by secobarbital or pentobarbital. JAMA 1958; 166:126-129.
10. Breimer DD: Clinical pharmacokinetics of hypnotics. ClinPharmacokinet 1977; 2:93-109.
11. Okamoto M: Barbiturate tolerance and physical dependence:Contribution of pharmacological factors. Natl Inst Drug Abuse Res MonogrSer 1984; 54:333-347
12. Grad R, Tamblyn R, Holbrook AM, et al. Risk of new benzodiazepine prescription in relation to recent hospitalization. J Am GeriatrSoc 1999;47:184-8
13. Zisberg A, Shadmi E, Sinoff G, et al. Hospitalization as a turning point for sleep medication use in older adults. Drugs Aging 2012;29:565-76
14. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults. JAMA 2006;295:2851-8
15. Joester J, Vogler CM, Chang K, et al. Hypnosedative use and predictors of successful withdrawal in new patients attending a falls clinic: a retrospective cohort study. Drugs Aging 2010;27: 915-24.
16. Salonoja M, Salminen M, Aarnio P, et al. One-time counselling decreases the use of benzodiazepines and related drugs among community-dwelling older persons. Age Ageing 2010; 39:313-9
17. Morgan K, Dixon S, Mathers N, et al. Psychological treatment for insomnia in management of longterm hypnotic drug use: a pragmatic randomized controlled trial. Br J Gen Pract 2003;53:923-8.
18. Morin CM, Bastien C, Guay B, et al. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry 2004;161:332-42.
19. Baillargeon L, Landreville P, Verreault R, et al. Discontinuation of benzodiazepines among older adults treated with cognitive-behavioral therapy combined with gradual tapering: a randomized trial. CMAJ 2003;169:1015-20
20. Voshaar RCO, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioral therapy: three-condition, randomized controlled trial. Br J Psychiatry 2003; 182:498-504.
21. Voshaar RCO, Gorgels WJ, Mol AJ, et al. Predictors of long-term benzodiazepine abstinence in participants of a randomized controlled benzodiazepine withdrawal program. Can J Psychiatry 2006;51:445-52
22. Vissers FH, Knipschild PG, Crebolder HF. Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. Pharm World Sci 2007;29:641-6
23. Garzón C, Guerrero JM, Aramburu O, et al. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging ClinExp Res 2009;21:38-42.
24. Dolder C, Nelson M, Mckinsey J. Use of non-benzodiazepine hypnotics in the elderly: Are all agents the same? CNS Drugs 2007;21:389-405.
25. Dailly E, Bourin M. The use of benzodiazepines in the aged patient: Clinical and pharmacological considerations. Pak J Pharm Sci 2008;21:144-50.
26. Lechevallier-Michel N, Gautier-Bertrand M, Alpérovitch A, Berr C, Belmin J, Legrain S, et al. Frequency and risk factors of potentially inappropriate medication use in a community-dwelling elderly population: Results from the 3C Study. Eur J Clin Pharmacol 2005;60:813-9.
27. Maczaj M. Pharmacological treatment of insomnia. CNS Drugs 1993;45:44-55
28. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 2004;3:485-93.

29. Stenbacka M, Jansson B, Leifman A, Romelsjö A. Association between use of sedatives or hypnotics, alcohol consumption, or other risk factors and a single injurious fall or multiple injurious falls: A longitudinal general population study. Alcohol 2002;28:9-16.
30. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 2004;3:485-93.
31. Sithamparanathan K, Sadera A, Leung L. Adverse effects of benzodiazepine use in elderly people: A meta analysis. Asian J Gerontol Geriatr 2012;7:107-11.
32. Yang YH, Lai JN, Lee CH, Wang JD, Chen PC. Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: A case-crossover study. J Epidemiol 2011;21:37-43.
33. Sharan P, Bharadwaj R, Grover S, Padhy SK, Kumar V, Singh J. Dependence syndrome and intoxication delirium associated with zolpidem. Natl Med J India 2007;20:180-1.
34. Pitner JK, Gardner M, Neville M, Mintzer J. Zolpidem-induced psychosis in an older woman. J Am Geriatr Soc 1997;45:533-4.
35. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001;49:1685-90.